Lynparza May Significantly Improve Outcomes for Ovarian Cancer Patients, Trial Shows
News
Certain ovarian cancer patients with BRCA mutations may benefit from maintenance treatment with the PARP inhibitor Lynparza (olaparib). The therapy significantly increases progression-free survival, according to the results of a ... Read more